The platform is protected by a composition-of-mater world-wide patent application (PCT), filed 2006, that broadly covers the scope of the invention. This patent was already granted by the US Patent Office, Nov. 2010 (US 7,838,513), and is now at the national phase in other countries. Tiltan Pharma owns the exclusive rights for these patents. In addition, Tiltan filed a new patent application, covering a more advanced therapy, now in clinical trial (PCT filed on 2013).
Tiltan was able to secure such a strong IP position on TL-118 even though each individual compound contained therein is commercially available, as both chemical and bioavailability properties require formulation and administration together under a unique setting, preventing off-label separate prescriptions of each drug.